SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on
the development and commercialization of new oncology therapeutics, today
announced that management will webcast a teleconference to review third
quarter progress and provide a general business update on Tuesday, November 4,
2008, at 11:00 a.m. ET / 8:00 a.m. PT.
Individual and institutional investors can access the call via
1-877-627-6566 (U.S. and Canada) or +1-719-325-4901 (international). To
access the live audio webcast or the subsequent archived recording, visit the
"Investors and Media - Calendar of Events" section of the Sunesis website at
http://www.sunesis.com.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and
commercialization of new oncology therapeutics for the treatment of solid and
hematologic cancers. Sunesis has built a highly experienced cancer drug
development organization committed to advancing its lead product candidate,
voreloxin, in multiple indications to improve the lives of people with cancer.
For additional information on Sunesis Pharmaceuticals, please visit
http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
Contact: Sunesis Pharmaceuticals, Inc.
Eric Bjerkholt
650-266-3717
SOURCE Sunesis Pharmaceuticals, Inc.
